Adverum Biotechnologies, Inc. (ADVM)Â
NASDAQ
Market Cap
$93.2M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
99 of 950
Rank in Industry
78 of 543
Largest Insider Buys in Sector
ADVM Stock Price History Chart
ADVM Stock Performance
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Activity of Adverum Biotechnologies, Inc.
Over the last 12 months, insiders at Adverum Biotechnologies, Inc. have bought $2.71M and sold $0 worth of Adverum Biotechnologies, Inc. stock.
On average, over the past 5 years, insiders at Adverum Biotechnologies, Inc. have bought $802,088 and sold $1.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $19.19M. Lupher, Jr. Mark L. (director) — $175,500. Scopa James Paul (director) — $135,000.
The last purchase of 85,800 shares for transaction amount of $613,470 was made by Leonard Braden Michael (10 percent owner) on 2024‑07‑30.
List of Insider Buy and Sell Transactions, Adverum Biotechnologies, Inc.
| 2024-07-30 | 10 percent owner | 85,800 0.3983% | $7.15 | $613,470 | +5.87% | |||
| 2024-07-18 | 10 percent owner | 80,718 0.3739% | $9.11 | $735,737 | -27.00% | |||
| 2024-07-17 | 10 percent owner | 135,546 0.5761% | $7.75 | $1.05M | -21.18% | |||
| 2024-02-07 | director | 130,000 0.1654% | $1.35 | $175,500 | -72.70% | |||
| 2024-02-07 | director | 100,000 0.1273% | $1.35 | $135,000 | -72.70% | |||
| 2023-09-15 | Sale | Chief Development Officer | 6,201 0.006% | $1.52 | $9,429 | -41.47% | ||
| 2023-06-07 | Chief Financial Officer | 100,000 0.098% | $1.45 | $145,490 | -18.95% | |||
| 2023-03-15 | Sale | CEO, President and Director | 41,239 0.0397% | $0.78 | $32,232 | +25.15% | ||
| 2023-03-15 | Sale | Chief Operating Officer | 13,360 0.0128% | $0.78 | $10,442 | +25.15% | ||
| 2023-03-15 | Sale | Chief Scientific Officer | 7,299 0.007% | $0.78 | $5,705 | +25.15% | ||
| 2022-05-23 | Chief Development Officer | 20,000 0.0205% | $0.84 | $16,800 | +0.48% | |||
| 2022-05-17 | Chief Medical Officer | 10,000 0.01% | $0.82 | $8,228 | +0.60% | |||
| 2022-05-16 | 30,000 0.0319% | $0.85 | $25,578 | +2.84% | ||||
| 2022-05-13 | Chief Financial Officer | 10,000 0.0104% | $0.86 | $8,585 | +0.06% | |||
| 2022-04-20 | CEO, President and Director | 25,000 0.0246% | $1.11 | $27,800 | -23.16% | |||
| 2022-04-19 | See Remarks section | 21,750 0.0224% | $1.14 | $24,795 | -21.79% | |||
| 2021-12-09 | CEO, President and Director | 14,323 0.0147% | $1.85 | $26,498 | -35.87% | |||
| 2021-12-08 | CEO, President and Director | 10,677 0.0104% | $1.79 | $19,112 | -36.90% | |||
| 2021-12-08 | See Remarks section | 25,000 0.026% | $1.91 | $47,750 | -36.90% | |||
| 2021-11-15 | Sale | director | 50,000 0.0512% | $2.18 | $109,000 | -41.71% |
Insider Historical Profitability
<0.0001%
| Leonard Braden Michael | 10 percent owner | 2268064 10.9028% | $4.48 | 3 | 0 | |
| Lupher, Jr. Mark L. | director | 130000 0.6249% | $4.48 | 1 | 0 | |
| Scopa James Paul | director | 100000 0.4807% | $4.48 | 3 | 1 | +22.77% |
| Zygtech, LLC | 10 percent owner | 2438176 11.7206% | $4.48 | 0 | 3 | |
| Venrock Associates VI, L.P. | 10 percent owner | 2365471 11.3711% | $4.48 | 1 | 0 | |
| Venrock Healthcare Capital Partners II, L.P. | 10 percent owner | 2365471 11.3711% | $4.48 | 1 | 0 | |
| REGENERON PHARMACEUTICALS INC | 10 percent owner | 1809098 8.6965% | $4.48 | 1 | 0 | |
| Fischer Laurent | CEO, President and Director | 692141 3.3272% | $4.48 | 6 | 1 | <0.0001% |
| Flynn James E | 10 percent owner | 654285 3.1452% | $4.48 | 1 | 0 | |
| Blumenkranz Mark S. | director | 522989 2.5141% | $4.48 | 0 | 13 | |
| Schwartz Steven Daniel | director | 367931 1.7687% | $4.48 | 0 | 7 | |
| Gasmi Mehdi | director | 274442 1.3193% | $4.48 | 0 | 22 | |
| Soparkar Peter | Chief Operating Officer | 265891 1.2782% | $4.48 | 3 | 1 | <0.0001% |
| Chalberg Thomas W. | Chief Executive Officer | 258988 1.245% | $4.48 | 0 | 3 | |
| Clark Julie | Chief Medical Officer | 164723 0.7918% | $4.48 | 0 | 1 | |
| Riley Brigit | Chief Scientific Officer | 117435 0.5645% | $4.48 | 0 | 1 | |
| Rubinstein Linda M | Chief Financial Officer | 100000 0.4807% | $4.48 | 1 | 0 | <0.0001% |
| PATTERSON LEONE D | President and CFO | 97955 0.4709% | $4.48 | 0 | 6 | |
| Machado Patrick | director | 88182 0.4239% | $4.48 | 2 | 0 | |
| Svoronos Dawn | 50000 0.2404% | $4.48 | 2 | 0 | +2.84% | |
| Seyedkazemi Setareh | Chief Development Officer | 47674 0.2292% | $4.48 | 1 | 1 | +0.48% |
| Wachter Paul | director | 37161 0.1786% | $4.48 | 0 | 11 | |
| Hull Hans | SVP, Business Operations | 11320 0.0544% | $4.48 | 0 | 3 | |
| D'Souza Rupert | Chief Financial Officer | 10850 0.0522% | $4.48 | 1 | 0 | +0.06% |
| Beckman Richard | Chief Medical Officer | 10000 0.0481% | $4.48 | 1 | 0 | +0.6% |
| Bain Linda | Chief Financial Officer | 9000 0.0433% | $4.48 | 0 | 4 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Tcg Crossover Management Llc | $28.4M | 9.68 | 2.01M | New | +$28.4M | 0.05 | |
| Vr Adviser Llc | $22.01M | 7.5 | 1.56M | -69.76% | -$50.78M | 1.07 | |
| Logos Global Management Lp | $21.21M | 7.23 | 1.5M | New | +$21.21M | 2.29 | |
| Vivo Capital | $21.21M | 7.23 | 1.5M | New | +$21.21M | 1.85 | |
| Frazier Life Sciences Management L P | $15.12M | 5.15 | 1.07M | New | +$15.12M | 0.68 | |
| The Vanguard Group | $12.83M | 4.37 | 907,151 | -78.34% | -$46.41M | <0.0001 | |
| Fidelity Investments | $12.73M | 4.34 | 900,527 | -85.3% | -$73.86M | <0.01 | |
| Bml Capital Management Llc | $11.78M | 4.01 | 833,117 | -81.71% | -$52.62M | 9.04 | |
| Franklin Templeton Investments | $9.55M | 3.26 | 675,675 | New | +$9.55M | <0.01 | |
| Commodore Capital, LP | $9.29M | 3.17 | 657,333 | -93.43% | -$132.11M | 0.04 | |
| Morgan Stanley | $7.95M | 2.71 | 562,035 | -89.09% | -$64.88M | <0.01 | |
| 5Am Venture Management Llc | $7.66M | 2.61 | 541,666 | New | +$7.66M | 0.51 | |
| Versant Ventures | $7.17M | 2.44 | 506,822 | -90% | -$64.5M | 6.95 | |
| Laurion Capital Management LP | $6.21M | 2.12 | 438,935 | New | +$6.21M | 0.04 | |
| Avoro Capital Advisors Llc | $5.89M | 2.01 | 416,666 | New | +$5.89M | 0.07 | |
| Assenagon Asset Management S.A. | $5.07M | 1.73 | 358,719 | New | +$5.07M | 0.01 | |
| BlackRock | $4.47M | 1.53 | 316,450 | -77.42% | -$15.34M | <0.0001 | |
| Samsara Biocapital Llc | $4.12M | 1.41 | 291,666 | New | +$4.12M | 0.64 | |
| Millennium Management LLC | $3.52M | 1.2 | 248,642 | -16.55% | -$697,031.32 | <0.01 | |
| Geode Capital Management | $2.74M | 0.93 | 193,516 | -77.61% | -$9.49M | <0.0001 | |
| Bank of America | $2.34M | 0.8 | 165,495 | -96.15% | -$58.46M | <0.0001 | |
| Aigh Capital Management Llc | $2.3M | 0.78 | 162,547 | -94.88% | -$42.57M | 1.31 | |
| Marshall Wace | $1.89M | 0.65 | 133,851 | New | +$1.89M | <0.01 | |
| Renaissance Technologies | $1.88M | 0.64 | 133,088 | -92.91% | -$24.67M | <0.01 | |
| Picton Mahoney Asset Management | $1.75M | 0.6 | 123,966 | New | +$1.75M | 0.09 | |
| State Street | $915,197.00 | 0.31 | 64,724 | -80.4% | -$3.75M | <0.0001 | |
| Barclays | $754,000.00 | 0.26 | 53,258 | New | +$754,000.00 | <0.0001 | |
| Citigroup | $743,835.00 | 0.25 | 52,605 | New | +$743,835.00 | <0.01 | |
| Newtyn Management | $653,112.00 | 0.22 | 46,189 | -94.39% | -$10.99M | 0.14 | |
| Qube Research & Technologies | $588,493.00 | 0.2 | 41,619 | +5,704.6% | +$578,354.61 | <0.01 | |
| Northern Trust | $519,504.00 | 0.18 | 36,740 | -79.63% | -$2.03M | <0.0001 | |
| Marathon Trading Investment Management Llc | $400,728.00 | 0.14 | 28,340 | New | +$400,728.00 | 0.08 | |
| Squarepoint Ops LLC | $384,184.00 | 0.13 | 27,170 | -35.82% | -$214,419.07 | <0.01 | |
| Quinn Opportunity Partners Llc | $379,362.00 | 0.13 | 26,829 | -93.26% | -$5.25M | 0.03 | |
| Dimensional Fund Advisors | $375,315.00 | 0.13 | 26,543 | -85.93% | -$2.29M | <0.0001 | |
| Shay Capital Llc | $330,805.00 | 0.11 | 23,395 | New | +$330,805.00 | 0.05 | |
| Walleye Capital | $231,458.00 | 0.08 | 16,369 | New | +$231,458.00 | <0.01 | |
| Two Sigma Advisers LP | $228,644.00 | 0.08 | 16,170 | -96.5% | -$6.31M | <0.0001 | |
| Cantor Fitzgerald L P | $218,406.00 | 0.07 | 15,446 | -90.23% | -$2.02M | <0.01 | |
| Balyasny Asset Management Llc | $200,760.00 | 0.07 | 14,198 | New | +$200,760.00 | <0.01 | |
| Two Sigma | $167,446.00 | 0.06 | 11,842 | -97.35% | -$6.14M | <0.0001 | |
| Charles Schwab | $151,482.00 | 0.05 | 10,713 | -70.58% | -$363,398.43 | <0.0001 | |
| Point72 Asia Singapore Pte Ltd | $131,168.00 | 0.05 | 9,276 | New | +$131,168.00 | 0.01 | |
| Group One Trading | $130,795.00 | 0.05 | 9,250 | -43.28% | -$99,785.98 | <0.01 | |
| Cubist Systematic Strategies | $119,945.00 | 0.04 | 8,483 | New | +$119,945.00 | <0.01 | |
| Acadian Asset Management | $41,000.00 | 0.01 | 2,902 | -89.61% | -$353,670.92 | <0.0001 | |
| Macquarie Group | $37,000.00 | 0.01 | 2,586 | New | +$37,000.00 | <0.0001 | |
| Advisor Group Holdings Inc | $28,987.00 | 0.01 | 2,050 | -97.96% | -$1.39M | <0.0001 | |
| Tower Research Capital | $14,183.00 | 0.01 | 1,003 | +45.15% | +$4,411.86 | <0.0001 | |
| UBS | $13,179.00 | <0.01 | 932 | +14.36% | +$1,654.44 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.